Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases

Abstract

This molecular fingerprint strongly argues against the clinical efficacy of BRAF-inhibitors, but could candidate primary sinonasal mucosal melanomas to therapeutic strategies targeting RAS and KIT mutations or inhibiting PI3K-Akt-mTOR pathway.